

Appendix 1

Question 1. The number of teenagers who have accessed the 1st jab, the number of teenagers who have accessed the 2nd jab, and the number of teenagers who have accessed the 3rd jab nationally since the launch of the HPV Immunisation Programme

1 st Dose	171,493
2 nd Dose	164,364
3 rd Dose	145,564

Question 2. The total cost of the programme paid by the Ministry of Health since its launch

Since the inception of the programme \$114,601,483 has been spent on vaccine, vaccine delivery costs, human papillomavirus health promotion and district health board school based and local programme costs and included a catch-up programme.

Question 3. The budgeted costs for the next 5 years

The projected five year cost of the human papillomavirus programme for the financial years 2012/2013 to 2016/2017, based on the current eligibility of girls aged 12 years to 19 years is \$43,527,241. This projected amount includes vaccine, vaccine delivery costs, HPV health promotion, district health board school-based programme costs and local programme costs. These projected costs may change depending on future contract prices for the vaccine, the number of vaccines given and the programme support costs over the next five years. The catch up programme has ended.

Question 4. What research has been undertaken in NZ to determine the effectiveness of the vaccine

Medsafe, a division of the Ministry of Health, is given information by the applicant wishing to distribute medicines in New Zealand. Clinical study information is included in the application.

Information on how Medsafe assesses the efficacy and safety of medicines, and its medicine classification process, can be found on its website at:

<http://www.medsafe.govt.nz/profs/class/clascon.asp>

For Gardasil, some New Zealanders were included in clinical studies conducted internationally. The information on these studies is publically available as explained below.

Question 5. What overseas research has been used to determine the effectiveness of the vaccine

This information is publically available, for example:

- in the data sheet:
<http://www.medsafe.govt.nz/profs/Datasheet/g/Gardasilinj.pdf>
- in public assessment reports:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000703/WC500021140.pdf
- the published scientific literature.
<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111287.pdf>

Question 6. The number of adverse reactions recorded since the launch of the programme

This information is publically available:

- <http://www.medsafe.govt.nz/Consumers/Safety-of-Medicines/Gardasil%20ADR%20data.asp>
- <http://www.medsafe.govt.nz/Projects/B1/ADRDisclaimer.asp>

RELEASED UNDER THE OFFICIAL INFORMATION ACT